Novel T-Cell Therapies Make Inroads Into Solid Tumors

Christin Melton, ELS
Published: Wednesday, Nov 28, 2018
Steven A.
Rosenberg, MD, PhD

Steven A. Rosenberg, MD, PhD

Today, the term immunotherapy is ubiquitous in discussions about cancer, but when Steven A. Rosenberg, MD, PhD, and colleagues at the National Cancer Institute (NCI) cured 33-year old Linda Taylor’s metastatic melanoma with infusions of interleukin 2 (IL-2) in 1984, immune-oncology was a nascent field.

award winner.

Figure. Categories of T-Cell–Based Immuno-Oncology Therapies1


Identifying the Right Targets

Solid tumors present several barriers to ACT efficacy that are largely absent in B-cell malignancies: heterogeneous antigen expression, a hostile immunosuppressive microenvironment, and sites that are difficult for the infused T cells to track to and infiltrate. The range of antigens expressed in solid tumors poses problems for both TIL and CAR T-cell therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication